Eradication of neutralizing antibodies to factor VIII in canine hemophilia A after liver gene therapy

Inhibitory antibodies to factor VIII (FVIII) are a major complication in the treatment of hemophilia A, affecting approximately 20% to 30% of patients. Current treatment for inhibitors is based on long-term, daily injections of large amounts of FVIII protein. Liver-directed gene therapy has been use...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Finn, Jonathan D., Ozelo, Margareth C., Sabatino, Denise E., Franck, Helen W. G., Merricks, Elizabeth P., Crudele, Julie M., Zhou, Shangzhen, Kazazian, Haig H., Lillicrap, David, Nichols, Timothy C., Arruda, Valder R.
Формат: Artigo
Язык:Inglês
Опубликовано: American Society of Hematology 2010
Предметы:
Gene Therapy
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC3031380/
https://ncbi.nlm.nih.gov/pubmed/20876851
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2010-06-288001
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы